The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature
Open Access
- 18 August 2017
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 2 (2) , 125-139
Abstract
Background Small cell lung cancer (SCLC), the most aggressive form of lung carcinoma, represents approximately 15% of all lung cancers; however, the economic and healthcare burden of SCLC is not well-defined. Objective The aim of this study was to explore the impact of SCLC on healthcare costs through a systematic literature review (SLR). Methods Using the OVID search engine, the SLR was conducted in PubMed, MEDLINE In–Process, EMBASE, EconLIT and the National Health Service Economic Evaluation Database (NHS EED). Searches were limited to studies published between January 2005 and 24 February 2016, and excluded preclinical studies. Additional internet-based searches were conducted. In total, 229 abstracts were retrieved and systematically screened for eligibility, with 17 publications retained. Results The majority of publications provided data on limited and extensive disease of SCLC. The reported burden was categorised as direct costs and indirect costs, with the majority of the publications (n = 16) reporting on direct costs and one reporting on both direct and indirect costs. The only indirect costs reported for SCLC were lost productivity (premature mortality costs) and caregiver burden. Chemotherapy, diagnostic costs and treatment costs were identified as significant costs when managing SCLC patients, including the associated treatment costs such as hospitalisation, nurse visits, emergency room visits, follow-up appointments and outpatient care. Conclusions SCLC and its treatment have a substantial impact on costs. The scarcity and heterogeneity of economic cost data negated meaningful cost comparison, highlighting the need for further research. Capturing the economic burden of SCLC may help patients and clinicians make informed treatment choices and improve SCLC management.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 38 references indexed in Scilit:
- Cost analysis of lung cancer management in South Western SydneyJournal of Medical Imaging and Radiation Oncology, 2012
- Topotecan for relapsed small cell lung cancer: A systematic review and economic evaluationCancer Treatment Reviews, 2011
- Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)Journal of Thoracic Oncology, 2011
- PCN101 INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG CANCER: ANALYSIS OF 2007 HEALTH CARE UTILIZATION AND PROJECT (HCUP) DATAValue in Health, 2010
- Review: Targeted therapies in small cell lung cancer: a reviewTherapeutic Advances in Medical Oncology, 2009
- Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapyCurrent Medical Research and Opinion, 2009
- PCN12 USE OF HEALTH RESOURCES IN LUNG CANCER PATIENTS: A BRAZILIAN ANALYSIS IN THE PRIVATE PAYER PERSPECTIVEValue in Health, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysisCurrent Medical Research and Opinion, 2008
- Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung CancerJournal of Clinical Oncology, 2006